Translating evidence into practice during the COVID-19 pandemic: pitfalls and mileages.
作者信息
Mangoni Arduino A, Erre Gian Luca
机构信息
Discipline of Clinical Pharmacology, College of Medicine and Public Health, Flinders University and Flinders Medical Centre, Bedford Park, SA 5042, Australia.
Dipartimento di Scienze Mediche, Università degli Studi di Sassari, Sassari, Italy, and Dipartimento di Specialità Mediche, Azienda Ospedaliero-Universitaria di Sassari, Sassari, Italy.
出版信息
Ther Adv Drug Saf. 2021 Mar 15;12:2042098621998876. doi: 10.1177/2042098621998876. eCollection 2021.
Abstract
摘要
相似文献
1
Translating evidence into practice during the COVID-19 pandemic: pitfalls and mileages.在新冠疫情期间将证据转化为实践：陷阱与成效
Ther Adv Drug Saf. 2021 Mar 15;12:2042098621998876. doi: 10.1177/2042098621998876. eCollection 2021.
2
Machine Learning Applications in Drug Repurposing.机器学习在药物再利用中的应用。
Interdiscip Sci. 2022 Mar;14(1):15-21. doi: 10.1007/s12539-021-00487-8. Epub 2022 Jan 23.
3
A New Approach to Drug Repurposing with Two-Stage Prediction, Machine Learning, and Unsupervised Clustering of Gene Expression.一种新的药物重定位方法，采用两阶段预测、机器学习和基因表达无监督聚类。
OMICS. 2022 Jun;26(6):339-347. doi: 10.1089/omi.2022.0026. Epub 2022 Jun 3.
4
SperoPredictor: An Integrated Machine Learning and Molecular Docking-Based Drug Repurposing Framework With Use Case of COVID-19.SperoPredictor：一种基于集成机器学习和分子对接的药物重定位框架，COVID-19 应用案例。
Front Public Health. 2022 Jun 16;10:902123. doi: 10.3389/fpubh.2022.902123. eCollection 2022.
5
Drug Repurposing During The COVID-19 Pandemic: Lessons For Expediting Drug Development And Access.新冠疫情期间的药物再利用：加速药物研发和获取的经验教训。
Health Aff (Millwood). 2023 Mar;42(3):424-432. doi: 10.1377/hlthaff.2022.01083.
6
Multi-Omics and Artificial Intelligence-Guided Drug Repositioning: Prospects, Challenges, and Lessons Learned from COVID-19.多组学和人工智能指导的药物重定位：从 COVID-19 中得到的前景、挑战和经验教训。
OMICS. 2022 Jul;26(7):361-371. doi: 10.1089/omi.2022.0068. Epub 2022 Jun 28.
7
Drug repurposing for COVID-19: Approaches, challenges and promising candidates.新冠病毒药物再利用：方法、挑战与有前景的候选药物。
Pharmacol Ther. 2021 Dec;228:107930. doi: 10.1016/j.pharmthera.2021.107930. Epub 2021 Jun 23.
8
Characterization and quantification of PM emissions and PAHs concentration in PM from the exhausts of diesel vehicles with various accumulated mileages.不同累计里程柴油车尾气颗粒排放物中 PM 及多环芳烃浓度的特征描述与量化。
Sci Total Environ. 2019 Apr 10;660:188-198. doi: 10.1016/j.scitotenv.2019.01.007. Epub 2019 Jan 5.
9
Viral pandemic preparedness: A pluripotent stem cell-based machine-learning platform for simulating SARS-CoV-2 infection to enable drug discovery and repurposing.病毒大流行防范：一种基于多能干细胞的机器学习平台，用于模拟 SARS-CoV-2 感染，以实现药物发现和再利用。
Stem Cells Transl Med. 2021 Feb;10(2):239-250. doi: 10.1002/sctm.20-0181. Epub 2020 Sep 22.
10
A comprehensive review of artificial intelligence and network based approaches to drug repurposing in Covid-19.人工智能和基于网络的方法在新冠病毒药物再利用中的综合综述
Biomed Pharmacother. 2022 Sep;153:113350. doi: 10.1016/j.biopha.2022.113350. Epub 2022 Jun 28.
引用本文的文献
1
Association between self-reported evidence-based medicine competencies and prescribing of drugs without scientific evidence against mild COVID-19 among recently graduated physicians in Peru.秘鲁近期毕业医生自我报告的循证医学能力与针对轻度新冠病毒疾病开具无科学依据药物处方之间的关联
Heliyon. 2023 Apr;9(4):e15366. doi: 10.1016/j.heliyon.2023.e15366. Epub 2023 Apr 8.
2
Activation of Sphingomyelinase-Ceramide-Pathway in COVID-19 Purposes Its Inhibition for Therapeutic Strategies.Sphingomyelinase-Ceramide-Pathway 在 COVID-19 中的激活使其成为治疗策略的抑制靶点。
Front Immunol. 2021 Dec 20;12:784989. doi: 10.3389/fimmu.2021.784989. eCollection 2021.
3
Serum hydroxybutyrate dehydrogenase and COVID-19 severity and mortality: a systematic review and meta-analysis with meta-regression.血清羟基丁酸脱氢酶与 COVID-19 严重程度和死亡率的关系：系统评价和荟萃分析及荟萃回归。
Clin Exp Med. 2022 Nov;22(4):499-508. doi: 10.1007/s10238-021-00777-x. Epub 2021 Nov 19.
本文引用的文献
1
Artificial Intelligence for COVID-19 Drug Discovery and Vaccine Development.用于新冠病毒药物研发和疫苗开发的人工智能
Front Artif Intell. 2020 Aug 18;3:65. doi: 10.3389/frai.2020.00065. eCollection 2020.
2
Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis.药物干预治疗 COVID-19 的疗效和安全性比较：系统评价和网络荟萃分析。
PLoS Med. 2020 Dec 30;17(12):e1003501. doi: 10.1371/journal.pmed.1003501. eCollection 2020 Dec.
3
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.托珠单抗治疗 COVID-19 住院患者的疗效。
N Engl J Med. 2020 Dec 10;383(24):2333-2344. doi: 10.1056/NEJMoa2028836. Epub 2020 Oct 21.
4
Efficacy and safety outcomes of proposed randomized controlled trials investigating hydroxychloroquine and chloroquine during the early stages of the COVID-19 pandemic.在 COVID-19 大流行早期阶段，研究羟氯喹和氯喹的拟议随机对照试验的疗效和安全性结果。
Br J Clin Pharmacol. 2021 Apr;87(4):1758-1767. doi: 10.1111/bcp.14598. Epub 2020 Nov 24.
5
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.羟氯喹治疗 COVID-19 住院患者的疗效。
N Engl J Med. 2020 Nov 19;383(21):2030-2040. doi: 10.1056/NEJMoa2022926. Epub 2020 Oct 8.
6
Global perspective of COVID-19 epidemiology for a full-cycle pandemic.COVID-19 流行病学的全球视角——全周期大流行。
Eur J Clin Invest. 2020 Dec;50(12):e13423. doi: 10.1111/eci.13423. Epub 2020 Oct 25.
7
Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial.羟氯喹与安慰剂对医护人员暴露前预防新型冠状病毒的疗效和安全性：一项随机临床试验
JAMA Intern Med. 2021 Feb 1;181(2):195-202. doi: 10.1001/jamainternmed.2020.6319.
8
Artificial intelligence in COVID-19 drug repurposing.人工智能在新冠病毒药物再利用中的应用。
Lancet Digit Health. 2020 Dec;2(12):e667-e676. doi: 10.1016/S2589-7500(20)30192-8. Epub 2020 Sep 18.
9
Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project).干预治疗 COVID-19：一项具有荟萃分析和试验序贯分析的实时系统评价（LIVING 项目）。
PLoS Med. 2020 Sep 17;17(9):e1003293. doi: 10.1371/journal.pmed.1003293. eCollection 2020 Sep.
10
SEeking AnsweRs for Care Homes during the COVID-19 pandemic (COVID SEARCH).新冠疫情期间的养老院问题研究（COVID SEARCH）。
Age Ageing. 2021 Feb 26;50(2):335-340. doi: 10.1093/ageing/afaa201.
Zotero 插件